IL158124A0 - Leishmania vaccines - Google Patents

Leishmania vaccines

Info

Publication number
IL158124A0
IL158124A0 IL15812402A IL15812402A IL158124A0 IL 158124 A0 IL158124 A0 IL 158124A0 IL 15812402 A IL15812402 A IL 15812402A IL 15812402 A IL15812402 A IL 15812402A IL 158124 A0 IL158124 A0 IL 158124A0
Authority
IL
Israel
Prior art keywords
leishmania
vaccines
leishmania vaccines
Prior art date
Application number
IL15812402A
Other languages
English (en)
Original Assignee
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcgill filed Critical Univ Mcgill
Publication of IL158124A0 publication Critical patent/IL158124A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL15812402A 2001-03-29 2002-03-27 Leishmania vaccines IL158124A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27942301P 2001-03-29 2001-03-29
PCT/CA2002/000437 WO2002078735A2 (en) 2001-03-29 2002-03-27 Leishmania vaccines

Publications (1)

Publication Number Publication Date
IL158124A0 true IL158124A0 (en) 2004-03-28

Family

ID=23068901

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15812402A IL158124A0 (en) 2001-03-29 2002-03-27 Leishmania vaccines

Country Status (7)

Country Link
US (1) US20040170636A1 (xx)
EP (1) EP1372705A2 (xx)
BR (1) BR0208532A (xx)
CA (1) CA2442298A1 (xx)
IL (1) IL158124A0 (xx)
MX (1) MXPA03008832A (xx)
WO (1) WO2002078735A2 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10314412A1 (de) * 2003-03-28 2004-10-14 Genovac Ag Genetische Immunisierung mit multiplen Expressionskonstrukten zur Herstellung von monoklonalen Antikörpern
US8968749B2 (en) 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
BRPI0603490B1 (pt) * 2006-07-21 2018-04-24 Universidade Federal De Minas Gerais Vacina recombinante contra a leishmaniose visceral canina
BRPI0800485B8 (pt) * 2008-01-17 2021-05-25 Univ Minas Gerais vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
EP2300051B1 (en) * 2008-05-21 2014-11-12 Infectious Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
US8410258B2 (en) 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
US11833197B2 (en) * 2018-02-13 2023-12-05 University Of Iowa Research Foundation Immunotherapy of leishmaniasis
US10898460B1 (en) 2018-07-20 2021-01-26 University Of South Florida Leishmania inhibitors
ES2795149B2 (es) 2020-06-08 2022-07-04 Univ Madrid Complutense Quimera sintetica multiepitopica como vacuna y tratamiento frente a leishmaniosis en mamiferos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236252T1 (de) * 1993-09-03 2003-04-15 Univ Mcgill Differentiell exprimierte leishmania gene und proteinen
NZ512730A (en) * 1998-12-04 2003-12-19 Univ Manitoba A immunization procedure against chlamydia infection using an attenuated bacteria comprsing a plasmid with a major outer membrane protein (MOMP) from chlamydial

Also Published As

Publication number Publication date
WO2002078735A3 (en) 2003-04-10
EP1372705A2 (en) 2004-01-02
US20040170636A1 (en) 2004-09-02
BR0208532A (pt) 2005-01-18
CA2442298A1 (en) 2002-10-10
MXPA03008832A (es) 2004-05-05
WO2002078735A2 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
HUP0402259A3 (en) Vaccines
AU2002336760A8 (en) Mutable vaccines
GB0130215D0 (en) Vaccine
AU4433702A (en) Vaccines
GB0407935D0 (en) Vaccine
HUP0303372A3 (en) Vaccine
EP1423141A4 (en) VACCINE
GB0306611D0 (en) Novel vaccine
GB0121171D0 (en) Vaccine
IL158124A0 (en) Leishmania vaccines
HUP0303878A3 (en) Smallpox vaccine
EP1429615A4 (en) ORAL VACCINES
GB0105238D0 (en) Vaccines
GB0108534D0 (en) Retaining means
GB0004533D0 (en) Vaccines
AU2002244589A1 (en) Leishmania vaccines
GB0113552D0 (en) Vaccines
GB2376939B (en) Retaining means
GB0129338D0 (en) Vaccination
GB0124137D0 (en) Vaccine
GB0106589D0 (en) Vaccine
GB0115496D0 (en) Vaccine
GB0128312D0 (en) Vaccine
GB0103867D0 (en) Vaccine
GB0130823D0 (en) Vaccine